Jefferies Upgrades Vera Therapeutics to Buy, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Farzin Haque has upgraded Vera Therapeutics from Hold to Buy and raised the price target from $18 to $26.
November 10, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has upgraded Vera Therapeutics to Buy and raised the price target, which could lead to increased investor interest and potential upward movement in the stock price.
The upgrade from Hold to Buy by Jefferies indicates a positive outlook for Vera Therapeutics. The raised price target from $18 to $26 suggests that the analyst sees significant upside potential for the stock. This could lead to increased investor interest and potential upward movement in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100